FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Providers who are unable to source TICE BCG will now be able to access rBCG through the expanded access program. Developed by the Serum Institute of India, the rBCG product, which has been ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz IntensifiesShares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
to supply a new Bacillus Calmette-Guérin (BCG) source for bladder cancer treatment in the U.S. This development comes as a response to the shortage of TICE® BCG, which has affected patient treatment ...
Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback